查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2100407

人工智慧在癌症診斷領域的市場－2026-2032年全球市場預測

AI in Cancer Diagnostics Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，用於癌症診斷的人工智慧市場將成長至 20.404 億美元，複合年成長率為 19.15%。

主要市場統計數據
基準年 2025 5.9839億美元
預計年份：2026年 710,830,000 美元
預測年份 2032 2,040,400,000 美元
複合年成長率 (%) 19.15%

人工智慧在癌症診斷領域的應用正在重塑臨床醫生在放射學、病理學、基因組學、內視鏡檢查、皮膚病學、細胞學以及多模態臨床決策支援等領域檢測、分類、分診和監測惡性腫瘤的方式。在那些需要進行大量影像檢查、複雜生物標記分析以及時間緊迫的診斷流程對醫療系統造成巨大負擔的領域，人工智慧的應用案例尤其增多。人工智慧驅動的癌症檢測工具正被應用於乳房X光檢查、肺結節評估、前列腺成像、子宮頸細胞學檢查、數位病理學、大腸鏡檢查輔助、皮膚病變評估和分子譜分析等領域，旨在提高診斷準確性、減少漏診、支持早期發現並規範不同醫療機構的診斷標準。

該領域的發展受到許多醫學優先事項的影響，包括癌症發病率上升、篩檢項目不斷擴大、許多國家放射科醫生和病理學家短缺、數位病理學的日益普及以及臨床實踐中影像和分子資料集的日益豐富。公共衛生機構一直將癌症列為全球主要死因之一，世界衛生組織（世衛組織）報告稱，每年新增癌症病例達數百萬例。因此，更早、更準確的診斷已成為醫療保健系統的策略重點。同時，監管機構正在加強對作為醫療設備的人工智慧軟體的審查，強調其臨床相關性、透明度、網路安全、偏差監測和上市後性能監測。

對於醫療服務提供者、實驗室、政策制定者和技術開發人員而言，機會不僅在於診斷任務的自動化，更在於將經臨床檢驗的人工智慧整合到可互通的工作流程中。最永續的部署模式是將人工智慧的輸出與醫生的決策、電子健康記錄、影像檔案、實驗室資訊系統、腫瘤學會議和品質保證程序相協調。隨著人工智慧在癌症診斷領域的不斷進步，證據生成、工作流程整合以及對臨床表現的信心仍然是影響其應用的核心因素。

人工智慧對癌症診斷的變革性影響

人工智慧在癌症診斷領域的發展趨勢正從實驗性演算法開發轉向臨床控制下的應用。其中一個主要轉變是從單一任務的影像分析轉向多模態人工智慧模型，後者融合了放射學、病理學、基因組學、臨床觀察、實驗室指標和病患病歷。這一趨勢反映了癌症治療的複雜性，診斷越來越依賴整合解剖學、組織學、分子生物學和臨床訊息，而非依賴單一資料來源。

人工智慧對癌症診斷的累積影響

人工智慧透過整合檢測、特徵分析、優先排序和治療計畫支援等功能，對整個癌症診斷流程產生累積影響。在篩檢，人工智慧可以識別可疑觀察，並提示放射科醫師和病理學家進行進一步檢查，有助於優先處理緊急病例並減少對觀察解讀的差異。在診斷影像領域，分割和量化工具有助於提高腫瘤和病灶測量的一致性，而風險分層模型在臨床醫生的指導下，則有助於指導後續治療建議。

人工智慧在癌症診斷中的關鍵區域性見解

在亞太地區，由於患者數量龐大、國家級癌症篩檢舉措不斷擴大、數位醫療基礎設施不斷完善以及政策層面高度重視醫療人工智慧，人工智慧輔助癌症診斷正迅速發展。儘管人工智慧在中國、印度、日本、韓國、澳洲和東南亞國協的醫療系統中，在放射科、病理科、內視鏡科和腫瘤科等醫療決策支援領域的應用日益廣泛，但其普及程度取決於醫院數位化進程、醫保報銷體系的發展以及資料管治的成熟度。該地區的優先事項包括：提高癌症早期篩檢的可及性、解決農村和二級醫療機構專家短缺問題，以及加強針對不同種族人口的人工智慧檢驗機制。

小組對人工智慧在癌症診斷中的應用的主要見解

儘管北約成員國並非單一的醫療保健集團，但它們擁有眾多先進的醫療保健系統，並致力於投資安全的數位基礎設施、網路安全、彈性醫療數據系統和可靠的數位轉型。這些優先事項直接影響人工智慧在高度敏感的診斷環境中的應用，這些環境需要強大的隱私保護和運作彈性，例如腫瘤影像、病理標本、基因組資料和病患記錄。對於與北約合作的醫療保健系統而言，人工智慧在癌症診斷中至關重要，因為它可以透過安全的數據交換、合規的軟體和臨床醫生指導的決策支援來改善放射學、病理學和篩檢工作流程。

主要國家癌症診斷中人工智慧的發展趨勢

中國是人工智慧在癌症診斷領域的重要力量，這得益於其大規模的臨床資料集、醫院數位化、國家級人工智慧政策以及在影像、病理、內視鏡和篩檢技術方面的積極發展。美國是人工智慧在癌症診斷領域最活躍的國家之一，這得益於其先進的癌症治療中心、完善的人工智慧醫療軟體監管流程、強大的影像和分子診斷基礎設施以及大規模的臨床研究基地。日本則在影像、內視鏡、病理和精準腫瘤學領域積極應用人工智慧，這得益於其高水平的臨床實踐、先進醫療技術的應用以及老齡化社會對癌症篩檢的迫切需求。

為人工智慧癌症診斷領域的領導者提供實用建議

產業領導者應優先考慮經臨床驗證、能夠解決特定診斷瓶頸的檢驗應用，而不是在未確保工作流程整合的情況下盲目追求廣泛的自動化。最有價值的應用領域包括篩檢分流、病灶檢測、病理品管、生物標記定量、報告標準化、病例優先排序、內視鏡輔助以及多學科腫瘤學支援。每一項實施都應從明確的用例、可衡量的性能指標、有記錄的人工監督以及監測其對診斷影響的計劃開始。

基於人工智慧的癌症診斷調查方法

嚴謹的人工智慧癌症診斷分析調查方法需要結合一手和二手研究、監管審查、臨床文獻評估以及專家檢驗。一手研究可能包括對放射科醫生、病理學家、腫瘤科醫生、實驗室主管、醫院管理人員、數位醫療負責人、監管專家和採購決策者進行結構化訪談。透過這些訪談，可以發現人工智慧在不同醫療環境中應用所面臨的障礙、工作流程需求、證據預期、應用風險以及臨床優先事項。

結論：人工智慧在癌症診斷的未來

人工智慧在癌症診斷領域的應用正進入一個關鍵階段，臨床可靠性、工作流程整合和負責任的管治與技術效能同等重要。這項技術已在影像學、病理學、內視鏡檢查、基因組學、細胞學、皮膚病學和多模態模式腫瘤學等領域展現出其在決策支援方面的價值，尤其是在幫助臨床醫生處理大量診斷工作、提高診斷一致性以及及早發現可疑觀察。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：癌症診斷領域的人工智慧市場：按組件分類

  • 硬體
    • 人工智慧伺服器和工作站
    • 高效能運算系統
    • 資料儲存中心
  • 服務
    • 託管服務
    • 專業服務
  • 軟體
    • 醫學影像軟體
    • 工作流程和報表軟體
    • 人工智慧模型開發平台

第8章：人工智慧在癌症診斷領域的市場：按癌症類型分類

  • 乳癌
  • 結腸癌
  • 肺癌
  • 攝護腺癌

第9章：人工智慧在癌症診斷領域的市場：按技術分類

  • 深度學習
  • 機器學習
  • 自然語言處理

第10章：人工智慧在癌症診斷領域的市場：按應用分類

  • 診斷影像
    • CT影像
    • 磁振造影
    • PET影像診斷
    • 超音波影像
  • 基因組分析
    • DNA定序
    • 表觀遺傳分析
    • RNA定序
  • 病理
    • 數位病理學
    • 組織病理學
  • 預測分析
    • 結果預測
    • 風險評估
  • 治療方案
    • 放射治療計劃
    • 手術計劃

第11章：癌症診斷領域的人工智慧市場：按最終用戶分類

  • 診斷檢查室
  • 醫院和診所
  • 製藥公司
  • 研究機構

第12章：人工智慧在癌症診斷領域的市場：按地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第13章：人工智慧在癌症診斷領域的市場：按群體分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第14章：人工智慧在癌症診斷領域的市場：按國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第15章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Abbott Laboratories Inc
  • Aidoc Medical
  • Aiforia Technologies
  • Azra AI
  • C the Signs
  • ConcertAI LLC
  • Enlitic Inc
  • F. Hoffmann-La Roche Ltd
  • Flatiron Health Inc
  • Foresight Diagnostics
  • GE HealthCare Technologies Inc.
  • GRAIL Inc
  • Ibex Medical Analytics
  • International Business Machines Corporation
  • Intuitive Surgical Inc
  • Kheiron Medical Technologies Limited
  • Koninklijke Philips NV
  • Lunit Inc
  • Medial EarlySign
  • Medtronic Plc
  • Microsoft Corporation
  • NVIDIA Corporation
  • Paige AI Inc
  • PathAI Inc
  • Qure.ai Technologies Private Limited
  • Siemens Healthineers AG
  • SkinVision
  • Tempus AI Inc
  • Viz.ai Inc
  • Zebra Medical Vision
Product Code: MRR-B16853776A7C

The AI in Cancer Diagnostics Market is projected to grow by USD 2,040.40 million at a CAGR of 19.15% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 598.39 million
Estimated Year [2026] USD 710.83 million
Forecast Year [2032] USD 2,040.40 million
CAGR (%) 19.15%

Artificial intelligence in cancer diagnostics is reshaping how clinicians detect, classify, triage, and monitor malignancies across radiology, pathology, genomics, endoscopy, dermatology, cytology, and multimodal clinical decision support. The strongest use cases are emerging where high-volume image interpretation, complex biomarker analysis, and time-sensitive diagnostic workflows create measurable pressure on health systems. AI-enabled cancer detection tools are being applied to mammography, lung nodule assessment, prostate imaging, cervical cytology, digital pathology, colonoscopy support, skin lesion evaluation, and molecular profiling, with the goal of improving diagnostic accuracy, reducing missed findings, supporting earlier detection, and standardizing interpretation across care settings.

The sector is being shaped by verified healthcare priorities: rising cancer incidence, expanding screening programs, shortages of radiologists and pathologists in many countries, growth in digital pathology adoption, and increasing availability of real-world imaging and molecular datasets. Public health agencies consistently identify cancer as one of the leading causes of death worldwide, while the World Health Organization has reported millions of new cancer cases annually, making earlier and more precise diagnosis a strategic priority for healthcare systems. At the same time, regulatory bodies are increasingly scrutinizing AI-based software as a medical device, emphasizing clinical validation, transparency, cybersecurity, bias monitoring, and post-market performance surveillance.

For healthcare providers, laboratories, policymakers, and technology developers, the opportunity lies not simply in automating diagnostic tasks but in embedding clinically validated AI into interoperable workflows. The most sustainable implementations align AI outputs with physician decision-making, electronic health records, imaging archives, laboratory information systems, tumor boards, and quality assurance programs. As AI in cancer diagnostics advances, evidence generation, workflow integration, and trust in clinical performance remain the core factors determining adoption.

Transformative Shifts in the AI Cancer Diagnostics Landscape

The AI in cancer diagnostics landscape is moving from experimental algorithm development toward clinically governed deployment. A major shift is the transition from single-task image analysis to multimodal AI models that combine radiology, pathology, genomics, clinical notes, laboratory values, and patient history. This movement reflects the complexity of oncology, where diagnosis increasingly depends on integrating anatomical, histological, molecular, and clinical context rather than relying on one data source alone.

Digital pathology is one of the most significant structural enablers. As laboratories digitize slides, AI can support tasks such as tumor detection, grading assistance, mitotic counting, biomarker quantification, margin assessment, and workload prioritization. In radiology, AI is increasingly used for lesion detection, segmentation, risk scoring, follow-up comparison, and triage in high-volume screening programs. In gastroenterology and dermatology, real-time AI assistance is improving the consistency of visual detection during colonoscopy and skin lesion assessment, while genomic AI supports variant interpretation and identification of actionable molecular patterns.

Another transformative shift is the growing importance of explainable, validated, and workflow-native AI. Healthcare organizations are moving beyond standalone dashboards toward integrated systems that fit within picture archiving and communication systems, digital slide viewers, laboratory workflows, and clinical decision support environments. Regulators and clinical users are also demanding evidence across diverse patient populations to reduce algorithmic bias and ensure reliable performance across age groups, ethnicities, imaging devices, sample preparation methods, and disease subtypes.

The commercial and clinical landscape is therefore being transformed by three forces: increased digitization of diagnostic data, heightened demand for earlier cancer detection, and stronger governance around AI safety and effectiveness. Organizations that can demonstrate reproducible clinical benefit, seamless integration, and continuous performance monitoring are best positioned in this evolving environment.

Cumulative Impact of Artificial Intelligence on Cancer Diagnosis

Artificial intelligence is having a cumulative impact across the cancer diagnostic pathway by connecting detection, characterization, prioritization, and treatment-planning support. In screening environments, AI can flag suspicious findings for radiologist or pathologist review, helping prioritize urgent cases and reduce variability in interpretation. In diagnostic imaging, segmentation and quantification tools support measurement consistency for tumors and lesions, while risk stratification models can help guide follow-up recommendations when used under clinician oversight.

In pathology, AI contributes to reproducibility in tasks that have traditionally depended on manual visual assessment. Quantitative image analysis can support biomarker scoring, tumor-infiltrating lymphocyte evaluation, tissue classification, and assessment of histologic patterns. These applications are particularly relevant as oncology moves toward precision medicine, where diagnostic conclusions increasingly influence targeted therapy eligibility, immunotherapy decisions, and enrollment in molecularly guided care pathways.

The cumulative effect of AI also extends to operational performance. Cancer diagnostic services face persistent pressures from workforce constraints, growing imaging volumes, and increasing complexity of molecular testing. AI can support workflow triage, quality control, report consistency, and turnaround time improvement when implemented with validated protocols. However, the technology does not replace specialist judgment; rather, it functions best as an assistive layer that supports clinicians while preserving accountability.

Ethical and regulatory considerations are central to this impact. AI systems must be monitored for dataset bias, clinical drift, false positives, false negatives, and performance changes across equipment and populations. Robust governance requires documented validation, audit trails, cybersecurity safeguards, explainability, human-in-the-loop oversight, and clear escalation pathways. The long-term value of AI in cancer diagnostics will depend on its ability to improve clinical reliability while maintaining patient safety, privacy, and equity.

Key Regional Insights for AI in Cancer Diagnostics

Asia-Pacific is advancing rapidly in AI-enabled cancer diagnostics due to large patient populations, expanding national cancer screening initiatives, growth in digital health infrastructure, and strong policy interest in medical AI. China, India, Japan, South Korea, Australia, and ASEAN healthcare systems are increasing the use of AI across radiology, pathology, endoscopy, and oncology decision support, although adoption varies by hospital digitization, reimbursement readiness, and data governance maturity. The region's priorities include improving access to early cancer detection, addressing specialist shortages in rural and secondary-care settings, and strengthening AI validation across ethnically diverse populations.

Europe is characterized by strong regulatory oversight, data protection requirements, and cross-border initiatives supporting trustworthy AI in healthcare. The European Union's medical device and AI governance frameworks are shaping how AI cancer diagnostic tools are validated, deployed, and monitored, while Europe's research networks and cancer plans are encouraging data-driven screening and precision oncology. Germany, France, Italy, Spain, and the United Kingdom are advancing digital pathology, imaging AI, and cancer screening innovation, with emphasis on clinical evidence, interoperability, patient data protection, and explainable AI.

North America remains a leading region for clinical validation, regulatory development, and integration of AI-based diagnostic software into advanced oncology workflows. The United States has an established pathway for reviewing software as a medical device, and healthcare institutions are using AI in breast imaging, lung cancer screening, digital pathology research, prostate imaging, colonoscopy support, and molecular diagnostics. Canada's approach emphasizes publicly funded health system integration, research collaboration, responsible AI governance, privacy, and equitable access across provinces and underserved populations.

Latin America is adopting AI in cancer diagnostics through a combination of private healthcare investment, telemedicine expansion, and public-sector interest in earlier detection. Brazil and Mexico are among the most active countries due to their large oncology burden and expanding diagnostic infrastructure. Key regional challenges include unequal access to advanced imaging, limited digital pathology deployment in some areas, fragmented data infrastructure, and the need for locally validated datasets that reflect regional demographics, cancer subtypes, and healthcare workflows.

Africa presents a highly important opportunity for AI cancer diagnostics because the region faces documented shortages of oncology specialists, pathologists, radiologists, screening infrastructure, and laboratory capacity in many health systems. AI can support telepathology, mobile health, cloud-based diagnostic assistance, cervical cancer screening, breast imaging triage, and remote specialist collaboration. However, implementation requires investment in connectivity, laboratory digitization, regulatory capacity, workforce training, ethical data governance, and locally representative training and validation data.

The Middle East is investing in AI-enabled healthcare as part of broader digital transformation strategies, especially in GCC countries where tertiary hospitals, electronic health records, national health modernization programs, and precision medicine initiatives are supporting diagnostic innovation. AI in oncology imaging and pathology is gaining attention as health systems seek faster diagnosis, specialist support, and high-quality cancer care. Regional success will depend on regulatory alignment, cybersecurity, interoperability, clinician adoption, and evidence generation within local populations.

Key Group Insights for AI in Cancer Diagnostics

NATO member countries, while not a healthcare bloc, include many advanced health systems that are investing in secure digital infrastructure, cybersecurity, resilient health data systems, and trusted digital transformation. These priorities directly affect AI deployment in sensitive diagnostic environments where oncology images, pathology slides, genomic data, and patient records require strong privacy protection and operational resilience. Across NATO-aligned health systems, AI in cancer diagnostics is most relevant where secure data exchange, regulated software, and clinician-supervised decision support can strengthen radiology, pathology, and screening workflows.

G7 countries are key adopters and regulators of AI-enabled cancer diagnostics because they have advanced healthcare systems, significant research capacity, mature oncology networks, and established regulatory frameworks for medical technologies. These countries are driving evidence standards for AI in radiology, pathology, genomics, endoscopy, and clinical decision support, with strong attention to patient safety, software lifecycle management, post-market monitoring, and real-world clinical validation. Their policies and clinical practices often influence broader international expectations for trustworthy AI in cancer detection.

BRICS countries represent a diverse but influential group for AI cancer diagnostics because they combine large cancer burdens, expanding digital health ecosystems, and strong interest in scalable diagnostic access. China and India are central to this momentum due to population scale, screening needs, hospital digitization, and growing medical AI capabilities, while Brazil, Russia, and South Africa are addressing diagnostic access gaps and oncology service capacity. The group's shared challenge is ensuring that AI tools are validated locally and integrated into practical clinical workflows, especially in settings with uneven infrastructure.

The European Union is shaping the global conversation on responsible AI through strict data protection requirements, medical device rules, and emerging AI governance standards. For AI in cancer diagnostics, this means developers and healthcare providers must prioritize clinical evidence, risk management, traceability, transparency, cybersecurity, and post-deployment monitoring. EU initiatives supporting health data spaces and interoperable digital infrastructure are relevant for oncology AI because high-quality, privacy-preserving datasets are essential for validating algorithms across diverse populations and care settings.

ASEAN is becoming an important growth environment for AI in cancer diagnostics as member countries expand hospital digitization, screening capacity, and telehealth infrastructure. Singapore is a regional center for medical AI governance and clinical research, while Indonesia, Thailand, Malaysia, Vietnam, and the Philippines are addressing cancer detection needs across large and geographically distributed populations. The most relevant AI applications in ASEAN include radiology triage, breast cancer screening support, cervical cancer detection, pathology workflow assistance, endoscopy support, and remote specialist collaboration.

The GCC is prioritizing AI-enabled cancer diagnostics within national digital health agendas, supported by investment in advanced hospitals, electronic health records, imaging infrastructure, and precision medicine initiatives. Health systems in the group are particularly focused on improving diagnostic quality, reducing time to treatment, building integrated oncology pathways, and expanding access to specialist-level interpretation. AI adoption is strongest where it aligns with centralized healthcare modernization, regulatory clarity, cybersecurity readiness, and specialist-led validation.

Key Country Insights for AI in Cancer Diagnostics

China is a major force in AI cancer diagnostics, supported by large clinical datasets, hospital digitization, national AI policy focus, and active development in imaging, pathology, endoscopy, and screening technologies. The United States is one of the most active countries for AI in cancer diagnostics, supported by advanced oncology centers, established regulatory pathways for AI-based medical software, strong imaging and molecular diagnostics infrastructure, and a large base of clinical research. Japan is applying AI in imaging, endoscopy, pathology, and precision oncology, supported by high clinical standards, advanced medical technology adoption, and an aging population with substantial cancer screening needs.

India has strong potential for AI cancer diagnostics because of its large patient population, uneven specialist distribution, expanding digital health architecture, and need for scalable early detection in breast, oral, cervical, and lung cancers. Germany has strong capabilities in medical engineering, hospital digitization, radiology AI, pathology innovation, and oncology research, with adoption shaped by clinical validation and data protection requirements. The United Kingdom is advancing AI in cancer imaging, pathology, and screening through national digital health initiatives and clinically oriented validation programs designed to improve earlier cancer detection and diagnostic productivity.

Australia is advancing AI in radiology, pathology, melanoma detection, and rural diagnostic support, with strong attention to clinical governance, patient safety, and equitable access across geographically dispersed communities. France is emphasizing health data governance, AI ethics, oncology research integration, and secure use of clinical datasets for innovation in imaging, pathology, and precision diagnostics. South Korea is a leading digital health and medical AI environment, with advanced hospital infrastructure, strong imaging capabilities, national digital health priorities, and growing use of AI in oncology workflows.

Italy and Spain are progressing in imaging AI, digital pathology pilots, cancer screening modernization, and oncology care transformation, although adoption depends on regional healthcare organization, procurement pathways, reimbursement readiness, and data infrastructure maturity. Canada is emphasizing responsible implementation within publicly funded healthcare, with attention to privacy, interoperability, real-world evidence, and equitable access across provinces, including underserved and remote populations. Russia is developing AI applications in radiology and public health diagnostics, with emphasis on imaging workflow support, centralized digital health systems, and deployment in major urban healthcare networks.

Brazil is a major Latin American adopter of AI-enabled cancer detection due to its large population, expanding private healthcare sector, academic medical capacity, and public health focus on breast, cervical, colorectal, lung, and prostate cancer diagnosis. Mexico is advancing digital health capabilities and cancer diagnostic modernization, with adoption shaped by urban-rural disparities, the need to expand screening access, and investment in imaging and telemedicine infrastructure. Across these countries, successful AI cancer diagnostics implementation depends on local clinical validation, interoperability, regulatory clarity, workforce readiness, and alignment with national cancer control priorities.

Actionable Recommendations for AI Cancer Diagnostics Leaders

Industry leaders should prioritize clinically validated AI applications that solve specific diagnostic bottlenecks rather than pursuing broad automation without workflow alignment. The highest-value opportunities include screening triage, lesion detection, pathology quality control, biomarker quantification, report standardization, case prioritization, endoscopy assistance, and multidisciplinary oncology support. Every deployment should begin with a clearly defined clinical use case, measurable performance criteria, documented human oversight, and a plan for monitoring diagnostic impact.

Healthcare organizations should establish AI governance committees that include clinicians, data scientists, compliance teams, information security leaders, laboratory specialists, patient safety experts, and ethics representatives. Governance should cover model validation, bias assessment, cybersecurity, data privacy, procurement criteria, user training, monitoring, and incident response. Because AI performance can change with population mix, scanner type, staining protocol, software updates, and disease prevalence, post-deployment surveillance is essential.

Technology developers should invest in diverse, high-quality datasets and transparent validation studies across multiple clinical sites. Evidence should demonstrate performance in real-world workflows, not only curated retrospective datasets. Developers should also design AI tools that integrate with existing radiology, pathology, laboratory, and electronic health record systems through recognized interoperability standards. Explainability, auditability, and clinician-friendly user interfaces are increasingly important for adoption.

Payers and policymakers should support reimbursement and procurement models that reward validated clinical value, improved diagnostic quality, and equitable access. Public-private collaboration can help build privacy-preserving data infrastructure, representative validation datasets, and training programs for clinicians using AI. For global expansion, leaders must localize AI tools to regional disease patterns, languages, clinical guidelines, care pathways, and regulatory requirements.

Research Methodology for AI in Cancer Diagnostics

A rigorous research methodology for analyzing AI in cancer diagnostics should combine primary research, secondary research, regulatory review, clinical literature assessment, and expert validation. Primary research may include structured interviews with radiologists, pathologists, oncologists, laboratory directors, hospital administrators, digital health leaders, regulatory experts, and procurement decision-makers. These discussions help clarify adoption barriers, workflow needs, evidence expectations, implementation risks, and clinical priorities across different healthcare settings.

Secondary research should draw from peer-reviewed medical literature, clinical guidelines, public health databases, regulatory submissions, government health strategies, medical device safety communications, hospital digital transformation reports, cancer screening policies, and standards bodies. Particular attention should be given to evidence from multicenter validation studies, prospective evaluations, real-world performance monitoring, and systematic reviews. Because AI tools can perform differently across populations and clinical environments, methodology should assess dataset diversity, external validation, comparator standards, and bias risk.

The research process should segment AI in cancer diagnostics by modality, cancer type, end-user, deployment environment, and clinical function. Relevant modalities include radiology, pathology, genomics, endoscopy, dermatology, cytology, and multimodal decision support. Clinical functions include detection, segmentation, classification, grading, triage, risk prediction, biomarker assessment, workflow prioritization, and quality assurance. End-users include hospitals, diagnostic laboratories, cancer centers, academic medical institutions, screening programs, and telemedicine networks.

Quality assurance should include triangulation of findings across multiple verified sources, exclusion of unsupported claims, and review by subject-matter specialists. Since this field evolves quickly, research should also track regulatory updates, clinical adoption evidence, AI safety guidance, data protection rules, cybersecurity expectations, and emerging standards for software as a medical device.

Conclusion: The Future of AI in Cancer Diagnostics

AI in cancer diagnostics is entering a critical phase in which clinical credibility, workflow integration, and responsible governance matter as much as technical performance. The technology is already demonstrating value across imaging, pathology, endoscopy, genomics, cytology, dermatology, and multimodal oncology decision support, particularly where it helps clinicians manage high diagnostic volumes, improve consistency, and identify suspicious findings earlier.

Regional adoption will continue to reflect differences in healthcare digitization, regulatory maturity, specialist availability, reimbursement structures, data protection requirements, and public trust in AI. Advanced health systems are setting standards for validation and governance, while emerging healthcare markets are exploring AI as a way to expand access to timely cancer diagnosis. Across all environments, the most successful implementations will be those that combine robust clinical evidence with explainable outputs, privacy protection, interoperability, cybersecurity, and continuous monitoring.

For industry leaders, the strategic imperative is clear: build and deploy AI cancer diagnostic tools that are clinically validated, ethically governed, locally adaptable, and designed around real-world diagnostic workflows. AI will not replace oncology specialists, radiologists, or pathologists; its long-term role is to strengthen their decision-making, improve diagnostic reliability, and support earlier, more equitable cancer detection.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. AI in Cancer Diagnostics Market, by Component

  • 7.1. Introduction
  • 7.2. Hardware
    • 7.2.1. AI Servers & Workstations
    • 7.2.2. High-Performance Computing Systems
    • 7.2.3. Data Storage Systems
  • 7.3. Services
    • 7.3.1. Managed Services
    • 7.3.2. Professional Services
  • 7.4. Software
    • 7.4.1. Diagnostic Imaging Software
    • 7.4.2. Workflow & Reporting Software
    • 7.4.3. AI Model Development Platforms

8. AI in Cancer Diagnostics Market, by Cancer Type

  • 8.1. Introduction
  • 8.2. Breast Cancer
  • 8.3. Colorectal Cancer
  • 8.4. Lung Cancer
  • 8.5. Prostate Cancer

9. AI in Cancer Diagnostics Market, by Technology

  • 9.1. Introduction
  • 9.2. Deep Learning
  • 9.3. Machine Learning
  • 9.4. Natural Language Processing

10. AI in Cancer Diagnostics Market, by Application

  • 10.1. Introduction
  • 10.2. Diagnostic Imaging
    • 10.2.1. CT Imaging
    • 10.2.2. MRI Imaging
    • 10.2.3. PET Imaging
    • 10.2.4. Ultrasound Imaging
  • 10.3. Genomic Profiling
    • 10.3.1. DNA Sequencing
    • 10.3.2. Epigenetic Analysis
    • 10.3.3. RNA Sequencing
  • 10.4. Pathology
    • 10.4.1. Digital Pathology
    • 10.4.2. Histopathology
  • 10.5. Predictive Analytics
    • 10.5.1. Outcome Prediction
    • 10.5.2. Risk Assessment
  • 10.6. Treatment Planning
    • 10.6.1. Radiotherapy Planning
    • 10.6.2. Surgical Planning

11. AI in Cancer Diagnostics Market, by End User

  • 11.1. Introduction
  • 11.2. Diagnostic Laboratories
  • 11.3. Hospitals And Clinics
  • 11.4. Pharmaceutical Companies
  • 11.5. Research Institutes

12. AI in Cancer Diagnostics Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. Europe
  • 12.3. North America
  • 12.4. Latin America
  • 12.5. Africa
  • 12.6. Middle East

13. AI in Cancer Diagnostics Market, by Group

  • 13.1. NATO
  • 13.2. G7
  • 13.3. BRICS
  • 13.4. European Union
  • 13.5. ASEAN
  • 13.6. GCC

14. AI in Cancer Diagnostics Market, by Country

  • 14.1. China
  • 14.2. United States
  • 14.3. Japan
  • 14.4. India
  • 14.5. Germany
  • 14.6. United Kingdom
  • 14.7. Australia
  • 14.8. France
  • 14.9. South Korea
  • 14.10. Italy
  • 14.11. Canada
  • 14.12. Russia
  • 14.13. Brazil
  • 14.14. Mexico
  • 14.15. Spain

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Abbott Laboratories Inc
  • 16.2. Aidoc Medical
  • 16.3. Aiforia Technologies
  • 16.4. Azra AI
  • 16.5. C the Signs
  • 16.6. ConcertAI LLC
  • 16.7. Enlitic Inc
  • 16.8. F. Hoffmann-La Roche Ltd
  • 16.9. Flatiron Health Inc
  • 16.10. Foresight Diagnostics
  • 16.11. GE HealthCare Technologies Inc.
  • 16.12. GRAIL Inc
  • 16.13. Ibex Medical Analytics
  • 16.14. International Business Machines Corporation
  • 16.15. Intuitive Surgical Inc
  • 16.16. Kheiron Medical Technologies Limited
  • 16.17. Koninklijke Philips N.V.
  • 16.18. Lunit Inc
  • 16.19. Medial EarlySign
  • 16.20. Medtronic Plc
  • 16.21. Microsoft Corporation
  • 16.22. NVIDIA Corporation
  • 16.23. Paige AI Inc
  • 16.24. PathAI Inc
  • 16.25. Qure.ai Technologies Private Limited
  • 16.26. Siemens Healthineers AG
  • 16.27. SkinVision
  • 16.28. Tempus AI Inc
  • 16.29. Viz.ai Inc
  • 16.30. Zebra Medical Vision

LIST OF FIGURES

  • FIGURE 1. GLOBAL AI IN CANCER DIAGNOSTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL AI IN CANCER DIAGNOSTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL AI IN CANCER DIAGNOSTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL AI IN CANCER DIAGNOSTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL AI IN CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HARDWARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HARDWARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HARDWARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL AI SERVERS & WORKSTATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL AI SERVERS & WORKSTATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AI SERVERS & WORKSTATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HIGH-PERFORMANCE COMPUTING SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HIGH-PERFORMANCE COMPUTING SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HIGH-PERFORMANCE COMPUTING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DATA STORAGE SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DATA STORAGE SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DATA STORAGE SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MANAGED SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MANAGED SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MANAGED SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PROFESSIONAL SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PROFESSIONAL SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PROFESSIONAL SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SOFTWARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SOFTWARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DIAGNOSTIC IMAGING SOFTWARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DIAGNOSTIC IMAGING SOFTWARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DIAGNOSTIC IMAGING SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL WORKFLOW & REPORTING SOFTWARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL WORKFLOW & REPORTING SOFTWARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL WORKFLOW & REPORTING SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL AI MODEL DEVELOPMENT PLATFORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL AI MODEL DEVELOPMENT PLATFORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL AI MODEL DEVELOPMENT PLATFORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COLORECTAL CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COLORECTAL CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COLORECTAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PROSTATE CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PROSTATE CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PROSTATE CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DEEP LEARNING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DEEP LEARNING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DEEP LEARNING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MACHINE LEARNING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MACHINE LEARNING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MACHINE LEARNING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NATURAL LANGUAGE PROCESSING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NATURAL LANGUAGE PROCESSING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NATURAL LANGUAGE PROCESSING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DIAGNOSTIC IMAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DIAGNOSTIC IMAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DIAGNOSTIC IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CT IMAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CT IMAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CT IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MRI IMAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MRI IMAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MRI IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PET IMAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PET IMAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PET IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ULTRASOUND IMAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ULTRASOUND IMAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ULTRASOUND IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GENOMIC PROFILING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GENOMIC PROFILING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL GENOMIC PROFILING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DNA SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DNA SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DNA SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL EPIGENETIC ANALYSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL EPIGENETIC ANALYSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL EPIGENETIC ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL RNA SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL RNA SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL RNA SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PATHOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PATHOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PATHOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL DIGITAL PATHOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL DIGITAL PATHOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL DIGITAL PATHOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL HISTOPATHOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL HISTOPATHOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL HISTOPATHOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PREDICTIVE ANALYTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PREDICTIVE ANALYTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PREDICTIVE ANALYTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL OUTCOME PREDICTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL OUTCOME PREDICTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL OUTCOME PREDICTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL RISK ASSESSMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL RISK ASSESSMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL RISK ASSESSMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL TREATMENT PLANNING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL TREATMENT PLANNING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL TREATMENT PLANNING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL RADIOTHERAPY PLANNING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL RADIOTHERAPY PLANNING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL RADIOTHERAPY PLANNING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL SURGICAL PLANNING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL SURGICAL PLANNING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL SURGICAL PLANNING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL HOSPITALS AND CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL HOSPITALS AND CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL HOSPITALS AND CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY GENOMIC PROFILING, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PREDICTIVE ANALYTICS, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TREATMENT PLANNING, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY GENOMIC PROFILING, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PREDICTIVE ANALYTICS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TREATMENT PLANNING, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY GENOMIC PROFILING, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PREDICTIVE ANALYTICS, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TREATMENT PLANNING, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY GENOMIC PROFILING, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PREDICTIVE ANALYTICS, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TREATMENT PLANNING, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY GENOMIC PROFILING, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PREDICTIVE ANALYTICS, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TREATMENT PLANNING, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST AI IN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST AI IN CANCER DIAGNOSTICS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST AI IN CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST AI IN CANCER DIAGNOSTICS MARKET SIZE, BY GENOMIC PROFILING, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PREDICTIVE ANALYTICS, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TREATMENT PLANNING, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 214. NATO AI IN CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 215. NATO AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 216. NATO AI IN CANCER DIAGNOSTICS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 217. NATO AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 218. NATO AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 219. NATO AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. NATO AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 221. NATO AI IN CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. NATO AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 223. NATO AI IN CANCER DIAGNOSTICS MARKET SIZE, BY GENOMIC PROFILING, 2018-2032 (USD MILLION)
  • TABLE 224. NATO AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 225. NATO AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PREDICTIVE ANALYTICS, 2018-2032 (USD MILLION)
  • TABLE 226. NATO AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TREATMENT PLANNING, 2018-2032 (USD MILLION)
  • TABLE 227. NATO AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. G7 AI IN CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 229. G7 AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 230. G7 AI IN CANCER DIAGNOSTICS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 231. G7 AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 232. G7 AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 233. G7 AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. G7 AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 235. G7 AI IN CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 236. G7 AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 237. G7 AI IN CANCER DIAGNOSTICS MARKET SIZE, BY GENOMIC PROFILING, 2018-2032 (USD MILLION)
  • TABLE 238. G7 AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 239. G7 AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PREDICTIVE ANALYTICS, 2018-2032 (USD MILLION)
  • TABLE 240. G7 AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TREATMENT PLANNING, 2018-2032 (USD MILLION)
  • TABLE 241. G7 AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY GENOMIC PROFILING, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PREDICTIVE ANALYTICS, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TREATMENT PLANNING, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION AI IN CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION AI IN CANCER DIAGNOSTICS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION AI IN CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION AI IN CANCER DIAGNOSTICS MARKET SIZE, BY GENOMIC PROFILING, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PREDICTIVE ANALYTICS, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TREATMENT PLANNING, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 271. ASEAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 272. ASEAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 274. ASEAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 275. ASEAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. ASEAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 277. ASEAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 278. ASEAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 279. ASEAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY GENOMIC PROFILING, 2018-2032 (USD MILLION)
  • TABLE 280. ASEAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 281. ASEAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PREDICTIVE ANALYTICS, 2018-2032 (USD MILLION)
  • TABLE 282. ASEAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TREATMENT PLANNING, 2018-2032 (USD MILLION)
  • TABLE 283. ASEAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 284. GCC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 285. GCC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 286. GCC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 287. GCC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 288. GCC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 289. GCC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. GCC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 291. GCC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 292. GCC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 293. GCC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY GENOMIC PROFILING, 2018-2032 (USD MILLION)
  • TABLE 294. GCC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 295. GCC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PREDICTIVE ANALYTICS, 2018-2032 (USD MILLION)
  • TABLE 296. GCC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TREATMENT PLANNING, 2018-2032 (USD MILLION)
  • TABLE 297. GCC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 298. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA AI IN CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 301. CHINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 302. CHINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 303. CHINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 304. CHINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 305. CHINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 306. CHINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 307. CHINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 308. CHINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY GENOMIC PROFILING, 2018-2032 (USD MILLION)
  • TABLE 309. CHINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 310. CHINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PREDICTIVE ANALYTICS, 2018-2032 (USD MILLION)
  • TABLE 311. CHINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TREATMENT PLANNING, 2018-2032 (USD MILLION)
  • TABLE 312. CHINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 313. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 314. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 315. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 317. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY GENOMIC PROFILING, 2018-2032 (USD MILLION)
  • TABLE 323. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 324. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PREDICTIVE ANALYTICS, 2018-2032 (USD MILLION)
  • TABLE 325. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TREATMENT PLANNING, 2018-2032 (USD MILLION)
  • TABLE 326. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 327. JAPAN AI IN CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 328. JAPAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 329. JAPAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 330. JAPAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 331. JAPAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 332. JAPAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 333. JAPAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 334. JAPAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 335. JAPAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 336. JAPAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY GENOMIC PROFILING, 2018-2032 (USD MILLION)
  • TABLE 337. JAPAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 338. JAPAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PREDICTIVE ANALYTICS, 2018-2032 (USD MILLION)
  • TABLE 339. JAPAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TREATMENT PLANNING, 2018-2032 (USD MILLION)
  • TABLE 340. JAPAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 341. INDIA AI IN CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 342. INDIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 343. INDIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 344. INDIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 345. INDIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 346. INDIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 347. INDIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 348. INDIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 349. INDIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 350. INDIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY GENOMIC PROFILING, 2018-2032 (USD MILLION)
  • TABLE 351. INDIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 352. INDIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PREDICTIVE ANALYTICS, 2018-2032 (USD MILLION)
  • TABLE 353. INDIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TREATMENT PLANNING,